Osteoarthritis – Global Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Osteoarthritis
– Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Osteoarthritis – Pipeline Review, H1 2019 provides
comprehensive information on the therapeutics under development for
Osteoarthritis (Musculoskeletal Disorders), complete with analysis by
stage of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Osteoarthritis (Musculoskeletal Disorders) pipeline guide also
reviews of key players involved in therapeutic development for
Osteoarthritis and features dormant and discontinued projects. The guide
covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and
Discovery stages are 8, 18, 19, 2, 44 and 12 respectively. Similarly,
the Universities portfolio in Phase I, Preclinical and Discovery stages
comprises 1, 6 and 7 molecules, respectively.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Osteoarthritis (Musculoskeletal Disorders).
• The pipeline guide reviews pipeline therapeutics for Osteoarthritis
  (Musculoskeletal Disorders) by companies and universities/research
  institutes based on information derived from company and
  industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Osteoarthritis
  (Musculoskeletal Disorders) therapeutics and enlists all their major
  and minor projects.
• The pipeline guide evaluates Osteoarthritis (Musculoskeletal
  Disorders) therapeutics based on mechanism of action (MoA), drug
  target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Osteoarthritis (Musculoskeletal Disorders).

Reasons to buy

• Procure strategically important competitor information, analysis, and
  insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under
  development for Osteoarthritis (Musculoskeletal Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of
  leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players
  and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding
  Osteoarthritis (Musculoskeletal Disorders) pipeline depth and focus of
  Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects
  and understand from the know-how what drove them from pipeline.

Companies Mentioned

• 4P-Pharma SAS
• AbbVie Inc
• Abiogen Pharma SpA
• Ablynx NV
• Akaal Pharma Pty Ltd
• Amgen Inc
• Anterogen Co Ltd
• Arthrogen BV
• AVM Biotechnology LLC
• Axsome Therapeutics Inc
• Bioiberica SAU
• Bone Therapeutics SA
• Can-Fite BioPharma Ltd
• Cellular Biomedicine Group Inc
• Chugai Pharmaceutical Co Ltd
• Corestem Inc
• Cynata Therapeutics Ltd
• Daewoong Pharmaceutical Co Ltd
• Eli Lilly and Co
• Ensol Biosciences Inc
• Evgen Pharma Plc
• Flexion Therapeutics Inc
• Galapagos NV
• Gemphire Therapeutics Inc
• Genequine Biotherapeutics GmbH
• GlaxoSmithKline Plc
• HSRx Group
• I-Mab Biopharma Co Ltd
• InKemia IUCT Group SA
• International Stem Cell Corp
• Jeil Pharmaceutical Co Ltd
• K-Stemcell Co Ltd
• Kang Stem Biotech Co Ltd
• Kolon TissueGene Inc
• Kukje Pharmaceutical Industry Co Ltd
• Lateral Pharma Pty Ltd
• Levolta Pharmaceuticals Inc
• LG Chem Ltd
• Link Health Group
• MediPost Co Ltd
• Medivir AB
• Medytox Inc
• Merck KGaA
• Mesoblast Ltd
• MetrioPharm AG
• Mor Research Applications Ltd
• Nordic Bioscience AS
• Novartis AG
• NovelMed Therapeutics Inc
• Paradigm Biopharmaceuticals Ltd
• and more…

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/gqd70u

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Musculoskeletal
Disorders Drugs